Skip to main content

Table 1 Characteristics of patients in Corrona who initiated a biologic DMARD, 2002–2019

From: The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy

  Biologic DMARD, any TCZ, any TCZm
N 7300 676 287
Age, median (IQR), years 58 (49, 66) 56 (46, 64) 56 (47, 65)
Female, n (%) 5667 (77.63) 539 (78.73) 233 (81.18)
Disease duration, median (IQR), years 5 (2, 12) 4 (1, 12) 5 (1, 12)
Seropositive*, n (%) 3783 (56.81) 303 (47.20) 131 (48.34)
Conventional DMARD use, n (%) 5994 (82.11) 521 (77.07) 200 (69.69)
Methotrexate 4873 (66.75) 414 (61.24) 149 (51.92)
Non-methotrexate csDMARDs 2414 (33.07) 232 (34.32) 95 (33.10)
Glucocorticoid use, any 2482 (34.00) 242 (35.80) 104 (36.24)
CDAI, median (IQR)** 15.6 (7.5, 25.8) 18.0 (9.9, 28.2) 18.4 (8.7, 28.0)
Remission, n (%) 642 (8.79) 36 (5.33) 16 (5.57)
Low disease activity, n (%) 1729 (23.68) 133 (19.67) 64 (22.30)
Moderate disease activity, n (%) 2362 (32.36) 226 (33.43) 86 (29.97)
High disease activity, n (%) 2298 (31.48) 265 (39.20) 113 (39.37)
HAQ, median (IQR)** 0.86 (0.25, 1.38) 1.00 (0.50, 1.63) 1.00 (0.50, 1.63)
Comorbidities, n (%)
Anemia 105 (1.44) 21 (3.11) 10 (3.48)
Asthma 113 (1.55) 9 (1.33) 5 (1.74)
Depression 317 (4.34) 38 (5.62) 17 (5.92)
Diabetes mellitus 279 (3.82) 30 (4.44) 12 (4.18)
Diarrhea 76 (1.04) 10 (1.48) 4 (1.39)
Dyspepsia 96 (1.32) 10 (1.48) 8 (2.79)
Fibromyalgia 111 (1.52) 18 (2.66) 8 (2.79)
Hepatic event 10 (0.14) 2 (0.30) 1 (0.35)
Hyperlipidemia 255 (3.49) 27 (3.99) 15 (5.23)
Hypertension 942 (12.90) 91 (13.46) 41 (14.29)
Nausea 86 (1.18) 9 (1.33) 4 (1.39)
Cancer 139 (1.90) 14 (2.07) 4 (1.39)
Stroke 61 (0.84) 7 (1.04) 4 (1.39)
Ulcer 188 (2.58) 21 (3.11) 12 (4.18)
Miscellaneous# 1313 (17.99) 98 (14.50) 43 (14.98)
  1. Disease duration information missing in 31 subjects
  2. HAQ Health Assessment Questionnaire version, TCZ tocilizumab, TCZm tocilizumab monotherapy, IQR inter-quartile range, DMARD disease-modifying anti-rheumatic drug
  3. *Seropositive defined as a positive rheumatoid factor or anti-CCP antibody, based on 6659 non-missing values
  4. **Clinical disease activity index (CDAI) categories defined as remission (CDAI <  2.8), low (CDAI 2.9–10.0), moderate (CDAI 10.1–22.0), and high (CDAI > 22.1)
  5. #Miscellaneous includes drug toxicity, fracture, and other less common comorbidities